Combined Protein C and Protein S Deficiency Presenting as Deep Vein Thrombosis
Back to listIntroduction
Venous thromboemboli arises in conditions of stasis, hypercoagulability, and acute trauma to venous endothelial surfaces. Hypercoagulable states may be acquired (antiphospholipid antibody syndrome, paroxysmal nocturnal hemoglobinuria, malignancy, pregnancy, nephrotic syndrome, or estrogen therapy) or inherited (prothrombin gene mutation, protein C and S deficiency, antithrombin III deficiency, factor V Leiden, or hyperhomocystinemia).
Abstract
Vitamin K dependent factors protein C and protein S act as anticoagulants by degrading the activated factors V and VIII. Deficiency of these factors, acquired or hereditary, are associated with increased risk of venous thrombosis. A patient having combined deficiency of both factors protein C and protein S is very rare. Here, we report a 59-year-old Asian female who presented with pain and swelling of the right lower extremities. Venous Doppler showed deep venous thrombus in the right femoral vein and further evaluation of coagulation profile showed combined deficiency of protein C and S. She was then started on long-term anticoagulant therapy. In conclusion, combined deficiency of protein C and protein S is extremely rare. Anticoagulation therapy is the cornerstone in the management of patients with inherited coagulation defects.
Keywords
deep vein thrombosis, protein C, protein S, combined deficiency
Other Articles
- Effect of Adjusted and Non-Adjusted Citrate Concentrations on Coagulation Test Results in Patients With High Hematocrit Values—Breaking the Unproven Leap of Faith
- The Off-Label Use of Recombinant FVIIa in the Treatment of a Patient With T-Cell Non-Hodgkin Lymphoma Who Developed Intra-abdominal and Intra-Pleural Hemorrhages Followed by High-Dose Methotreaxate Therapy
- Prophylaxis with Once, Twice or Three-Times Weekly Dosing of rFVIII-FS prevents Joint Bleeds in a Previously Treated Pediatric Population with Moderate/Severe Hemophilia A
- Current Practice in Clinical Thrombosis and Hemostasis
- Review of the Literature of FEIBA Administration in Patients with Hemophilia B and Inhibitors
